<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01560234</url>
  </required_header>
  <id_info>
    <org_study_id>D0542C00001</org_study_id>
    <secondary_id>Eudract number 2011-005986-20</secondary_id>
    <nct_id>NCT01560234</nct_id>
  </id_info>
  <brief_title>AZD8848 Single Ascending Dose Study</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of single ascending doses of AZD8848 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability,
      Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy
      Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Screening up to Day 13</time_frame>
    <description>Summary of number of subjects who had at least one adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary for Lymphocytes Laboratory Results</measure>
    <time_frame>Baseline, Day 1, Day 2, Day 3, and Follow up (up to Day 13)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC (Nmol*h/L)</measure>
    <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC(0-t) (Nmol*h/L)</measure>
    <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - Cmax (Nmol/L)</measure>
    <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</measure>
    <time_frame>Baseline, 24 Hours.</time_frame>
    <description>Smmarizes the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</measure>
    <time_frame>Baseline, 48 Hours</time_frame>
    <description>Smmarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistical Assessment of CXCL10 Ratio-to-baseline- Sputum</measure>
    <time_frame>Baseline, 24 Hours.</time_frame>
    <description>Summarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD8848</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8848</intervention_name>
    <description>Single dose, oral inhalation (nebuliser solution)</description>
    <arm_group_label>AZD8848</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose, oral inhalation (nebuliser solution)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women aged 18 to 45 years (inclusive) with suitable veins for
             cannulation or repeated venipuncture.

          -  Women can be of childbearing potential and must have been stable on a highly effective
             contraceptive method for at least 3 months prior to Visit 1 (screening) and be willing
             to continue on the chosen contraceptive method

          -  Male subjects should be willing to use a condom (with spermicide) to prevent pregnancy
             and drug exposure of a female partner and refrain from donating sperm or fathering a
             child from the day of the investigational product administration until 3 months

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no
             more than 100 kg

          -  Ability to produce sputum of good enough quality for assessment of biomarkers

        Exclusion Criteria:

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following
             (SBP &gt; 140 mmHg, Diastolic blood pressure (DBP) &gt; 90 mmHg, Heart rate &lt; 40 or &gt; 85
             beats per minute)

          -  Prolonged QTcF &gt; 450 ms or shortened QTcF &lt; 340 ms or family history of long QT
             syndrome

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the Investigator or history of hypersensitivity to drugs with a similar
             chemical structure or class as AZD8848

          -  History of additional risk factors for Torsade de pointes (e.g., heart failure,
             hypokalaemia, family history of Long QT syndrome, or sudden death)

          -  History of asthma or allergic rhinitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Aggarwal</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D, 35 Gatehouse Drive, MA 02451 USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Ritter, BA,MA D Phil,BM BCh,MRCP,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintile Drug Research Unit at Guy's Hospital Quintiles Ltd 6 Newcomen Street London SE1 1YR United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1660&amp;filename=D0542C00001_CSR.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <results_first_submitted>July 30, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>inhaled</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 47 male and female subjects (6 cohorts with additional 2 cohorts) were randomized in the study.There were 6 subjects per cohort (4 subjects received AZD8848 and 2 subjects received placebo), with the exception of Cohort 3 (1.5 μg), where 3 subjects received AZD8848 and 2 subjects received placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Commercial 0.9% sodium chloride solution.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1</title>
          <description>AZD8848 0.15 μg</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2</title>
          <description>AZD8848 0.5 ug</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3</title>
          <description>AZD8848 1.5 μg</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4</title>
          <description>AZD8848 5 μg</description>
        </group>
        <group group_id="P6">
          <title>Cohort 5</title>
          <description>AZD8848 15 μg</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7</title>
          <description>AZD8848 15 μg (Multiple Inhalation)</description>
        </group>
        <group group_id="P8">
          <title>Cohort 6 and 8</title>
          <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All available data were used for the baseline analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Commercial 0.9% sodium chloride solution.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1</title>
          <description>AZD8848 0.15 μg</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2</title>
          <description>AZD8848 0.5 ug</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3</title>
          <description>AZD8848 1.5 μg</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4</title>
          <description>AZD8848 5 μg</description>
        </group>
        <group group_id="B6">
          <title>Cohort 5</title>
          <description>AZD8848 15 μg</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7</title>
          <description>AZD8848 15 μg (Multiple Inhalation)</description>
        </group>
        <group group_id="B8">
          <title>Cohort 6 and 8</title>
          <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="6"/>
                    <measurement group_id="B2" value="29" spread="10"/>
                    <measurement group_id="B3" value="23" spread="3"/>
                    <measurement group_id="B4" value="24" spread="5"/>
                    <measurement group_id="B5" value="31" spread="4"/>
                    <measurement group_id="B6" value="27" spread="6"/>
                    <measurement group_id="B7" value="30" spread="9"/>
                    <measurement group_id="B8" value="31" spread="9"/>
                    <measurement group_id="B9" value="28" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject characteristics (Height)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.1" spread="7.1"/>
                    <measurement group_id="B2" value="168.6" spread="1.7"/>
                    <measurement group_id="B3" value="170.5" spread="8.5"/>
                    <measurement group_id="B4" value="167.7" spread="15.5"/>
                    <measurement group_id="B5" value="166.0" spread="5.0"/>
                    <measurement group_id="B6" value="175.0" spread="8.3"/>
                    <measurement group_id="B7" value="169.3" spread="11.1"/>
                    <measurement group_id="B8" value="176.9" spread="8.6"/>
                    <measurement group_id="B9" value="170.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject characteristics (Weight)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" spread="11.2"/>
                    <measurement group_id="B2" value="76.9" spread="6.7"/>
                    <measurement group_id="B3" value="68.2" spread="12.2"/>
                    <measurement group_id="B4" value="71.4" spread="5.0"/>
                    <measurement group_id="B5" value="67.7" spread="14.2"/>
                    <measurement group_id="B6" value="78.1" spread="16.3"/>
                    <measurement group_id="B7" value="69.4" spread="10.5"/>
                    <measurement group_id="B8" value="79.3" spread="8.0"/>
                    <measurement group_id="B9" value="73.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject characteristics (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.81" spread="2.71"/>
                    <measurement group_id="B2" value="27.02" spread="1.94"/>
                    <measurement group_id="B3" value="23.41" spread="3.50"/>
                    <measurement group_id="B4" value="25.63" spread="3.16"/>
                    <measurement group_id="B5" value="24.48" spread="4.46"/>
                    <measurement group_id="B6" value="25.31" spread="3.47"/>
                    <measurement group_id="B7" value="24.41" spread="4.87"/>
                    <measurement group_id="B8" value="25.40" spread="2.37"/>
                    <measurement group_id="B9" value="25.01" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Summary of number of subjects who had at least one adverse event</description>
        <time_frame>Screening up to Day 13</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Summary of number of subjects who had at least one adverse event</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC (Nmol*h/L)</title>
        <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC (Nmol*h/L)</title>
          <population>Pharmacokinetic Population</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.149" spread="22.9"/>
                    <measurement group_id="O6" value="0.360" spread="43.4"/>
                    <measurement group_id="O7" value="0.312" spread="26.2"/>
                    <measurement group_id="O8" value="0.642" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>AUC (nmol*h/L) 5 to 30 μg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC(0-t) (Nmol*h/L)</title>
        <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - AUC(0-t) (Nmol*h/L)</title>
          <population>Pharmacokinetic Population</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.131" spread="22.1"/>
                    <measurement group_id="O6" value="0.328" spread="46.2"/>
                    <measurement group_id="O7" value="0.279" spread="26.6"/>
                    <measurement group_id="O8" value="0.591" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>AUC(0-t) (nmol*h/L) 5 to 30 μg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - Cmax (Nmol/L)</title>
        <time_frame>On Day 1 at 0min, 2min, 5min, 10min, 20min, 30min, 45min, 60min, 90min, 2h, 4h, 6h, 8h, 12h, 24h and 48h</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary (Geometric Mean and GCV%) of Pharmacokinetic Parameters of Total AZ12432045 - Cmax (Nmol/L)</title>
          <population>Pharmacokinetic Population</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0362" spread="10.3"/>
                    <measurement group_id="O4" value="0.0903" spread="40.8"/>
                    <measurement group_id="O5" value="0.473" spread="36.1"/>
                    <measurement group_id="O6" value="0.963" spread="47.0"/>
                    <measurement group_id="O7" value="0.629" spread="13.6"/>
                    <measurement group_id="O8" value="1.67" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Cmax (nmol/L) 0.5 to 30 μg</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</title>
        <description>Smmarizes the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
        <time_frame>Baseline, 24 Hours.</time_frame>
        <population>Pharmacodynamic Population Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</title>
          <description>Smmarizes the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
          <population>Pharmacodynamic Population Set</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9290" spread="10.4" lower_limit="0.7703" upper_limit="1.120"/>
                    <measurement group_id="O2" value="0.9267" spread="107.7" lower_limit="0.6381" upper_limit="1.346"/>
                    <measurement group_id="O3" value="0.8638" lower_limit="0.5949" upper_limit="1.254"/>
                    <measurement group_id="O4" value="0.9869" lower_limit="0.6417" upper_limit="1.518"/>
                    <measurement group_id="O5" value="1.355" lower_limit="0.9332" upper_limit="1.967"/>
                    <measurement group_id="O6" value="2.079" lower_limit="1.412" upper_limit="3.059"/>
                    <measurement group_id="O7" value="2.120" lower_limit="1.460" upper_limit="3.078"/>
                    <measurement group_id="O8" value="6.354" lower_limit="4.880" upper_limit="8.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour Plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>99.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.76</ci_lower_limit>
            <ci_upper_limit>151.32</ci_upper_limit>
            <estimate_desc>Cohort 1/0.15 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hour Plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>92.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.21</ci_lower_limit>
            <ci_upper_limit>141.27</ci_upper_limit>
            <estimate_desc>Cohort 2/1.5ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>24 hour Plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>145.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.11</ci_lower_limit>
            <ci_upper_limit>221.28</ci_upper_limit>
            <estimate_desc>Cohort 4/5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hour Plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>106.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.42</ci_lower_limit>
            <ci_upper_limit>169.93</ci_upper_limit>
            <estimate_desc>Cohort 3/1.5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>24 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>223.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>144.98</ci_lower_limit>
            <ci_upper_limit>345.35</ci_upper_limit>
            <estimate_desc>Cohort 5/15 μg vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>24 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>228.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>150.36</ci_lower_limit>
            <ci_upper_limit>346.41</ci_upper_limit>
            <estimate_desc>Cohort 7/15 μg vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>24 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>684.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>495.31</ci_lower_limit>
            <ci_upper_limit>944.65</ci_upper_limit>
            <estimate_desc>Cohort 6 and 8/30 μg vs Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</title>
        <description>Smmarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
        <time_frame>Baseline, 48 Hours</time_frame>
        <population>Pharmacodynamic Population Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistical Assessment of CXCL10 Ratio-to-baseline - Plasma</title>
          <description>Smmarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
          <population>Pharmacodynamic Population Set</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" spread="10.4" lower_limit="0.8914" upper_limit="1.142"/>
                    <measurement group_id="O2" value="0.9669" spread="107.7" lower_limit="0.7552" upper_limit="1.238"/>
                    <measurement group_id="O3" value="0.9256" lower_limit="0.7229" upper_limit="1.185"/>
                    <measurement group_id="O4" value="1.134" lower_limit="0.8524" upper_limit="1.508"/>
                    <measurement group_id="O5" value="1.211" lower_limit="0.9460" upper_limit="1.550"/>
                    <measurement group_id="O6" value="1.036" lower_limit="0.8020" upper_limit="1.338"/>
                    <measurement group_id="O7" value="1.482" lower_limit="1.158" upper_limit="1.897"/>
                    <measurement group_id="O8" value="2.422" lower_limit="2.034" upper_limit="2.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>95.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.70</ci_lower_limit>
            <ci_upper_limit>126.28</ci_upper_limit>
            <estimate_desc>Cohort 1/0.15 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>48 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>91.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>69.53</ci_lower_limit>
            <ci_upper_limit>121.00</ci_upper_limit>
            <estimate_desc>Cohort 2/0.5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>48 hour Plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>112.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.30</ci_lower_limit>
            <ci_upper_limit>153.35</ci_upper_limit>
            <estimate_desc>Cohort 3/1.5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>48 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>120.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.04</ci_lower_limit>
            <ci_upper_limit>158.18</ci_upper_limit>
            <estimate_desc>Cohort 4/5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>48 hour placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>102.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.02</ci_lower_limit>
            <ci_upper_limit>136.87</ci_upper_limit>
            <estimate_desc>Cohort 5/15 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>48 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>146.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>111.39</ci_lower_limit>
            <ci_upper_limit>193.62</ci_upper_limit>
            <estimate_desc>Cohort 7/15 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hour plasma</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of Placebo</param_type>
            <param_value>240.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>193.82</ci_lower_limit>
            <ci_upper_limit>297.28</ci_upper_limit>
            <estimate_desc>Cohort 6 and 8/30 ug</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary for Lymphocytes Laboratory Results</title>
        <time_frame>Baseline, Day 1, Day 2, Day 3, and Follow up (up to Day 13)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary for Lymphocytes Laboratory Results</title>
          <population>Safety Analysis Set</population>
          <units>cells*10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.3"/>
                    <measurement group_id="O2" value="1.7" spread="0.5"/>
                    <measurement group_id="O3" value="2.0" spread="0.6"/>
                    <measurement group_id="O4" value="2.1" spread="0.5"/>
                    <measurement group_id="O5" value="2.3" spread="0.7"/>
                    <measurement group_id="O6" value="2.1" spread="0.3"/>
                    <measurement group_id="O7" value="1.9" spread="0.3"/>
                    <measurement group_id="O8" value="1.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.5"/>
                    <measurement group_id="O2" value="2.1" spread="0.7"/>
                    <measurement group_id="O3" value="2.7" spread="0.7"/>
                    <measurement group_id="O4" value="2.2" spread="0.3"/>
                    <measurement group_id="O5" value="2.4" spread="0.6"/>
                    <measurement group_id="O6" value="2.4" spread="0.6"/>
                    <measurement group_id="O7" value="2.0" spread="0.4"/>
                    <measurement group_id="O8" value="1.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.4"/>
                    <measurement group_id="O2" value="2.0" spread="0.6"/>
                    <measurement group_id="O3" value="1.9" spread="0.3"/>
                    <measurement group_id="O4" value="2.0" spread="1.5"/>
                    <measurement group_id="O5" value="2.2" spread="0.7"/>
                    <measurement group_id="O6" value="2.0" spread="0.3"/>
                    <measurement group_id="O7" value="1.4" spread="0.3"/>
                    <measurement group_id="O8" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.5"/>
                    <measurement group_id="O2" value="2.0" spread="0.6"/>
                    <measurement group_id="O3" value="2.1" spread="0.2"/>
                    <measurement group_id="O4" value="2.0" spread="0.6"/>
                    <measurement group_id="O5" value="2.3" spread="1.0"/>
                    <measurement group_id="O6" value="2.0" spread="0.1"/>
                    <measurement group_id="O7" value="1.7" spread="0.1"/>
                    <measurement group_id="O8" value="1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up (up to Day 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.4"/>
                    <measurement group_id="O2" value="2.0" spread="0.5"/>
                    <measurement group_id="O3" value="2.1" spread="0.5"/>
                    <measurement group_id="O4" value="1.8" spread="0.3"/>
                    <measurement group_id="O5" value="2.1" spread="0.8"/>
                    <measurement group_id="O6" value="1.9" spread="0.2"/>
                    <measurement group_id="O7" value="1.7" spread="0.3"/>
                    <measurement group_id="O8" value="1.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statistical Assessment of CXCL10 Ratio-to-baseline- Sputum</title>
        <description>Summarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
        <time_frame>Baseline, 24 Hours.</time_frame>
        <population>Pharmacodynamic Population Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Commercial 0.9% sodium chloride solution.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>AZD8848 0.15 μg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>AZD8848 0.5 ug</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>AZD8848 1.5 μg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4</title>
            <description>AZD8848 5 μg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 5</title>
            <description>AZD8848 15 μg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7</title>
            <description>AZD8848 15 μg (Multiple Inhalation)</description>
          </group>
          <group group_id="O8">
            <title>Cohort 6 and 8</title>
            <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
          </group>
        </group_list>
        <measure>
          <title>Statistical Assessment of CXCL10 Ratio-to-baseline- Sputum</title>
          <description>Summarize the statistical assessment comparing active CXCL10 ratio to baseline to placebo at each dose level, sampling time, and matrix</description>
          <population>Pharmacodynamic Population Set</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.038" spread="10.4" lower_limit="0.5929" upper_limit="1.818"/>
                    <measurement group_id="O2" value="1.192" spread="107.7" lower_limit="0.4145" upper_limit="3.430"/>
                    <measurement group_id="O3" value="0.8500" lower_limit="0.2976" upper_limit="2.428"/>
                    <measurement group_id="O4" value="0.8465" lower_limit="0.2396" upper_limit="2.991"/>
                    <measurement group_id="O5" value="3.160" lower_limit="0.9011" upper_limit="11.08"/>
                    <measurement group_id="O6" value="2.012" lower_limit="0.7055" upper_limit="5.737"/>
                    <measurement group_id="O7" value="4.858" lower_limit="1.704" upper_limit="13.85"/>
                    <measurement group_id="O8" value="11.29" lower_limit="3.792" upper_limit="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>114.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.83</ci_lower_limit>
            <ci_upper_limit>378.78</ci_upper_limit>
            <estimate_desc>Cohort 1/0.15 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>81.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.96</ci_lower_limit>
            <ci_upper_limit>268.70</ci_upper_limit>
            <estimate_desc>Cohort 2/0.5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>81.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.63</ci_lower_limit>
            <ci_upper_limit>322.42</ci_upper_limit>
            <estimate_desc>Cohort 3/1.5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>304.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.61</ci_lower_limit>
            <ci_upper_limit>1209.33</ci_upper_limit>
            <estimate_desc>Cohort 4/5 ug vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>193.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.01</ci_lower_limit>
            <ci_upper_limit>636.49</ci_upper_limit>
            <estimate_desc>Cohort 5/15 μg vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>467.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>142.77</ci_lower_limit>
            <ci_upper_limit>1533.92</ci_upper_limit>
            <estimate_desc>Cohort 7/15 μg vs Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>24 hour Sputum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Comparison of Placebo</param_type>
            <param_value>1087.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>317.19</ci_lower_limit>
            <ci_upper_limit>3727.57</ci_upper_limit>
            <estimate_desc>Cohort 6 and 8/30 μg vs Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening up to 11 - 13 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Commercial 0.9% sodium chloride solution.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1</title>
          <description>AZD8848 0.15 μg</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2</title>
          <description>AZD8848 0.5 ug</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3</title>
          <description>AZD8848 1.5 μg</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4</title>
          <description>AZD8848 5 μg</description>
        </group>
        <group group_id="E6">
          <title>Cohort 5</title>
          <description>AZD8848 15 μg</description>
        </group>
        <group group_id="E7">
          <title>Cohort 7</title>
          <description>AZD8848 15 μg (Multiple Inhalation)</description>
        </group>
        <group group_id="E8">
          <title>Cohort 6 and 8</title>
          <description>AZD8848 30 μg (similar investigational product administration conditions)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pelvic Inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a publication (e.g., in a scientific journal) based on the results of this study is envisaged, approval from AstraZeneca will be obtained and a draft manuscript will be submitted to AstraZeneca for scrutiny and comment. The choice of conduit will be mutually agreed on by the Principal Investigator and AstraZeneca.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ajay Aggarwal</name_or_title>
      <organization>AstraZeneca R&amp;D</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

